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Anterior gradient 2 downregulation in a subset of
pancreatic ductal adenocarcinoma is a prognostic factor
indicative of epithelial–mesenchymal transition
Yusuke Mizuuchi1,2, Shinichi Aishima1, Kenoki Ohuchida3, Koji Shindo1,2, Minoru Fujino1, Masami Hattori1,
Tetsuyuki Miyazaki1, Kazuhiro Mizumoto4, Masao Tanaka3 and Yoshinao Oda1
Anterior gradient 2 (AGR2), a member of the protein disulfide isomerase family, has been implicated in various cancers
including pancreatic ductal adenocarcinoma (PDAC) and is known to promote cancer progression. However, the
prognostic value of AGR2 expression and the interaction with epithelial–mesenchymal transition (EMT) remain unclear.
We investigated the clinical significance of AGR2 and EMT markers in PDAC patients by immunohistochemical analyses.
Although AGR2 expression was not observed in normal pancreas, all pancreatic precursor neoplastic lesions were positive
for AGR2, even at the earliest stages, including pancreatic intraepithelial neoplasia-1A, AGR2 expression was reduced in
27.7% (54/195 cases) of PDAC patients. AGR2 downregulation correlated with EMT markers (vimentin overexpression and
reduced membranous E-cadherin expression), high Union for International Cancer Control stage (Po0.0001), high
histological cellular grade (Po0.0001), and adverse outcome (Po0.0001). In vitro, targeted silencing of AGR2 in cancer
cells using siRNA reduced cell proliferation, colony formation, cell invasiveness, and migration, but did not alter EMT
markers. To confer a more aggressive phenotype and induce EMT in PDAC cells, we co-cultured PDAC cell lines with
primary-cultured pancreatic stellate cells (PSCs) and found that AGR2 was downregulated in co-cultured PDAC cells
compared with PDAC monocultures. Treatment with transforming growth factor beta-1 (TGF-b), secreted from PSCs,
decreased AGR2 expression, whereas inhibition of TGF-b signaling using recombinant soluble human TGF-b receptor type
II and TGF-b-neutralizing antibodies restored AGR2 expression. We conclude that AGR2 downregulation is a useful
prognostic marker, induced by EMT, and that secreted TGF-b from PSCs may partially contribute to AGR2 downregulation
in PDAC patients. AGR2 downregulation does not induce EMT or a more aggressive phenotype, but is a secondary effect
of these processes in advanced PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the
leading causes of cancer death in the United States, with an
overall survival rate of 3–5%.1 Early recurrence following
resection is associated with high mortality, and to date, few
treatment options are available. Thus, the development of
novel markers for early detection and prognosis prediction
is necessary to improve the management of patients with
PDAC. Understanding of the progression from precursors
to invasive disease has significantly advanced, following the
identification of three important precursors, including pancreatic
intraepithelial neoplasia (PanIN), intraductal papillary muci-
nous neoplasms (IPMNs), and mucinous cystic neoplasms.
However, the mechanisms underlying the progression from
these precursors to invasive disease remain unclear.2–4
Anterior gradient genes were first identified in Xenopus
laevis and are named according to their specific expression
patterns during embryonic development.5,6 Anterior gradient
2 (AGR2) homolog expression is responsible for the develop-
ment of the cement gland, a glandular organ in frog embryos,
and for limb regeneration in newts.7,8 In humans, the AGR2
gene lies at chromosomal position 7p21.3, and gives rise to
an 18-kDa-sized protein. AGR2 is classified as a member of
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the protein disulfide isomerase family, involved in protein
maturation and folding, on the basis of structural similarity.9
Several studies have shown that AGR2 is overexpressed
and promoted tumor progression in numerous human
malignancies affecting the ovary, breast, lung, prostate, and
pancreas.10–14
In PDAC, Ramanchandran et al.14 reported that AGR2
expression was elevated, even in PanIN1A, the earliest
precursor lesion of PDAC. In this context, AGR2 promotes
cancer cell proliferation, invasion, and resistance to chemo-
therapy, suggesting that AGR2 promotes cancer progression;
however, the mechanisms underlying AGR2 function in
advanced PDAC remain unclear. The prognostic value of
AGR2 expression in PDAC is controversial.15 Previous
reports have also shown that AGR2 promotes dissemina-
tion of pancreatic cancer via regulation of lysosomal pro-
teases (cathepsin B and D); however, conversely, AGR2
expression is decreased in PDAC compared with PanIN.16
Epithelial–mesenchymal transition (EMT), a well-known
hallmark of highly invasive cancer cells, is a critical pheno-
typic alteration involved in the morphological change from
epithelial to mesenchymal phenotype. Emerging evidence
suggests that the acquisition of a mesenchymal phenotype
has a key role in migration, invasion, resistance to chemo-
radiotherapy, and extravasation of cancer cells from the
primary tumor microenvironment.17 Other studies have
revealed that decreased membranous expression and cyto-
plasmic translocation of E-cadherin provide an indication
of EMT.18,19 Furthermore, EMT is correlated with high
histological grade in breast and pancreatic cancer.20 To the
best of our knowledge, however, there are no studies address-
ing the correlation between AGR2 expression and EMT
induction.
The tumor microenvironment, which is composed of
immune cells, fibroblastic cells, blood vessels, and extra-
cellular matrix in cancer stroma, closely interacts with cancer
cells invading the stroma. Pancreatic stellate cells (PSCs),
having myofibroblastic morphology in activated state, are
located in the pancreatic stroma and have an important
role in the pancreatic cancer microenvironment.21 The
interaction between pancreatic cancer cells and PSCs
promotes cancer cell proliferation, migration, and invasion
via the secretion of soluble factors, such as transforming
growth factor beta-1 (TGF-b1), epidermal growth factor
(EGF), and fibroblast growth factor 2 (FGF-2), which
are well-characterized EMT-inducible factors.22–26 A recent
report demonstrated that PSCs also promote EMT in pan-
creatic cancer cells.27
In this study, we aim to verify whether AGR2 expression
represents a useful prognostic marker in human PDAC, and
whether its downregulation is mediated by EMT induction.
We identified a correlation between AGR2 expression, EMT
marker expression, and clinic-pathological parameters in
PDAC. Our study also shows that preserved AGR2 expression
is a favorable prognostic factor in PDAC.
MATERIALS AND METHODS
Patients and Tissue Samples
Formalin-fixed, paraffin-embedded surgical resection sam-
ples (PDAC, n¼ 195, PanIN, n¼ 15, and IPMN, n¼ 39) were
obtained from patients who were diagnosed and underwent
pancreatic resection at our institution between July 1999 and
March 2009. Forty variants of pancreatic cancer including
adenosquamous carcinoma (n¼ 4), adenocarcinoma with
squamous differentiation (n¼ 6), anaplastic carcinoma (n¼ 3),
and acinar cell carcinoma (n¼ 1) were excluded from this
study. The study protocol was approved by the Ethics
Committee of Kyushu University (approval number 24–222,
25–117) and conformed to the Ethical Guidelines for Human
Genome/Gene Research enacted by the Japanese Government
and the Declaration of Helsinki. For strict privacy protection,
identifying information for all patients was removed before
analysis.
Immunohistochemical Analysis
Primary antibodies used for immunohistochemical (IHC)
analysis were as follows: AGR2 (rabbit polyclonal, IMG-5279A,
1/100 dilution, IMGENEX, San Diego, CA, USA), vimentin
(mouse monoclonal, Clone V9, 1/25 dilution, DAKOCytomation,
Glostrup, Denmark) and E-cadherin (mouse monoclonal,
610181, 1/1000 dilution, BD Biosciences, Franklin Lakes, NJ,
USA). Antibodies were diluted in 5% dry skimmed milk in
PBS. In brief, 5-mm-thick tissue sections were deparaffinized
in xylene and dehydrated in ethanol. Endogenous peroxidase
activity was blocked by incubation in methanol containing
0.3% H2O2 for 30min. Antigen retrieval was achieved by
boiling slides in a microwave in 10mM citrate buffer (pH
6.0) for 20min (AGR2 and E-cadherin only). The slides were
then incubated with primary antibodies at 4 1C overnight
and subsequently incubated with biotin-free horseradish
peroxidase enzyme-labeled polymer (Envision plus System,
DAKO Cytomation) for 40min at room temperature. The
labeled antigens were visualized using 3,30-diaminobenzidine
tetrahydrochloride as a chromogen. Counterstaining was
performed with hematoxylin. Appropriate positive and
negative controls were performed for all antibodies. Non-
specific staining was not observed in any negative-control
sections.
Evaluation of Immunohistochemical Staining
All tissue sections were assessed by two investigators (YM and
SA) who were blinded to patient clinicopathological results.
AGR2 immunoreactivity was determined using an intensity
score, graded on a scale from 0 to 3, and a proportional score,
corresponding to the percentage of stained cells (0: no
staining, 1:o20%; 2: 20–50%, and 3:450%), as previously
described.16 The total score was the product of intensity and
the proportional score. AGR2 high-expressing patients scored
between 4 and 6 (n¼ 139) and low-expressing patients
between 0 and 3 (n¼ 54). Membranous immunoreactivity
for E-cadherin was categorized as high expression (450% of
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cells staining positive, similar to normal epithelial cells) or
low expression (o50% of cells staining positive), as pre-
viously described.28 Cytoplasmic expression of vimentin was
categorized as positive if any cancer cell exhibited positive
immunoreactivity and as negative if there was complete
absence of vimentin staining.
Cells and Culture Conditions
The following pancreatic cancer cell lines were used in this
study: HPC-3, H48N (Dr H Iguchi, National Shikoku Cancer
Center, Matsuyama, Japan), Panc-1 (Riken Cell Bank, Tsukuba,
Japan), SUIT-2, MIA PaCa-2 (Japanese Cancer Resource
Bank, Osaka, Japan), HS766T, BxPC-3, Capan-2, Aspc-1, and
CFPAC-1 (American Type Culture Collection, Manassas, VA,
USA). Human PSCs were isolated from PDAC surgical
specimens using the outgrowth method as previously
described.21 Primary cultures of PSCs derived from PDAC
patients were established in our laboratory. These cells
exhibited a fibroblast-like morphology, and immuno-
fluorescence analysis revealed that the majority of cells were
positive for vimentin and alpha-smooth muscle actin
(490%), markers of activated fibroblasts and glial fibrillary
acidic protein, a marker of PSCs, and negative for cytokeratin
19, a marker of epithelial cells (Supplementary Figure 1). All
established PSCs were used between passages 3 and 7. All cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Life Technology, Grand Island, NY, USA) sup-
plemented with 10% fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA, USA), streptomycin (100mg/ml) and peni-
cillin (100mg/ml) and grown at 37 1C in a humidified
atmosphere containing 10% CO2.
Western Blotting
Protein was extracted from cell lines using lysis buffer (PRO-
PREP Protein Extraction Solution, iNtRON Biotechnology,
Seongnam, South Korea), and lysates (20 mg) were separated
by SDS-PAGE and transferred to polyvinylidene difluoride
membranes (Immobilon P, Millipore, Bedford, MA, USA).
Membranes were blocked with 5% dry skimmed milk and
incubated with primary antibodies; anti-AGR2 rabbit poly-
clonal antibody (1:500, IMGENEX), anti-E-cadherin mouse
polyclonal antibody (1:5000, BD Biosciences), anti-vimentin
mouse monoclonal antibody (1:500, DAKO Cytomation),
anti-phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) rabbit
monoclonal antibody (#8828, 1:1000, Cell Signaling Techno-
logy, Danvers, MA, USA), anti-Smad2/3 rabbit monoclonal
antibody (#8685, 1:1000, Cell Signaling Technology), anti-
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) rabbit
monoclonal antibody (#4370, 1:2000, Cell Signaling Tech-
nology), and anti-p44/42 MAPK (Erk1/2) rabbit monoclonal
antibody (#4695, 1:1000, Cell Signaling Technology) using
the SNAP i.d. Protein Detection System (Millipore) in accor-
dance with the manufacturer’s instructions. Anti-glyceraldehyde
3-phosphate dehydrogenase antibody (mouse monoclonal,
sc32233, 1/5000 dilution, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) was used as an internal control.
Membranes were then incubated with anti-rabbit IgG (#7074,
1/5000 dilution, Cell Signaling Technology), anti-mouse IgG1
(sc-2061, 1/3000 dilution, Santa Cruz Biotechnology), and
anti-mouse IgG2a (sc-2061, 1/3000 dilution, Santa Cruz
Biotechnology). Immunoreactive signals were detected using
ECL Prime (GE Healthcare, Buckinghamshire, UK) and
images were acquired using a ChemiDoc XRS (Bio-Rad
Laboratories, Hercules, CA, USA).
Quantitative RT-PCR (qRT-PCR)
qRT-PCR was performed as previously described.29 Total
RNA was isolated from cancer cell lines using the High
Pure RNA Isolation Kit (Roche Diagnostics, Mannheim,
Germany) with DNase I (Roche Diagnostics) treatment, in
accordance with the manufacturer’s instructions. RNA was
quantified by measuring absorbance at 260 nm, and purity
was evaluated from the 260/280 ratio of absorbance using
a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). qRT-PCR was
performed using the QuantiTect SYBR Green Reverse
Transcription-PCR kit (Qiagen, Tokyo, Japan) and a CFX96
Touch Real-Time PCR Detection System (Bio-Rad Laboratories).
Data are presented as relative expression normalized to 18S
rRNA levels. The primer sequences are listed in Supple-
mentary Table 1.
Immunofluorescence Staining
Primary-cultured PSCs were seeded in 35-mm glass-bottom
dishes (Matsunami, Osaka, Japan) (2 104 cells/dish) in
DMEM with 10% FBS and incubated for 24 h. Cells were
then fixed with methanol, blocked with 3% bovine serum
albumin in PBS, and incubated with either anti-alpha-
smooth muscle actin antibody (rabbit polyclonal, ab5694,
1/100 dilution, Abcam, Cambridge, MA, USA), anti-
vimentin antibody (mouse monoclonal, clone V9, 1/50
dilution, Dako), anti-glial fibrillary acidic protein antibody
(mouse monoclonal, ab10062, 1/100 dilution, Abcam), and
anti-cytokeratin 19 antibody (goat polyclonal, sc-33111,
1/5000 dilution, Santa Cruz Biotechnology) overnight at
4 1C. Cells were then incubated with Alexa 488-conjugated
anti-mouse IgG (A11029, Molecular Probes, Eugene, OR,
USA), 546-conjugated anti-rabbit IgG (A11035, Molecular
Probes), or 546-conjugated anti-goat IgG (A11056, Mole-
cular Probes) for 1 h. Nuclear DNA was counterstained
with 40,6-diamidino-2-phenylindole (0.05 mg/ml) (Dojindo,
Kumamoto, Japan). Fluorescence was visualized using an
All-in-one Type Fluorescence Microscope (BZ-9000; Keyence
Corporation, Osaka, Japan), and images were acquired using
BZ-II image analysis software (Keyence).
AGR2 Knockdown by Small-Interfering RNA (siRNA)
siRNA targeting AGR2 (On-Target plus Smart Pool siRNAs-
siAGR2) and non-targeting siRNA control (ON-TARGET
plus non-targeting siRNA) were purchased from Dharmacon
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(Chicago, IL, USA). Transfection was performed according to
the manufacturer’s reverse-transfection protocol using Lipo-
fectamine RNAiMAX (Life Technology). In brief, siRNAs and
Lipofectamine (5 ml) were diluted in 500 ml Opti-MEM (Life
Technology) without serum, and incubated for 10min at
room temperature. Cancer cells (3 105) were resuspended
in 2.5ml of DMEM supplemented with 10% FBS without
antibiotics. The siRNA and Lipofectamine mixture was added
to the diluted cells (3ml final volume, final siRNA con-
centration 2 nM for Aspc-1 cells and 10 nM for Panc-1,
Hs766T, Capan-2, and BxPC-3 cells) and seeded in six-well
plates (3 105 cells/well). After 24-h incubation, plates were
washed and cells were incubated in complete growth medium
(DMEM with 10% FBS and antibiotics) for various time
points. Cancer cells were used in subsequent experiments
48 h post transfection.
Proliferation Assays
Cancer cell lines were seeded in 24-well plates (1 104 cells/
well) (Becton Dickinson, Bedford, MA, USA) in DMEM
containing 10% FBS. Following incubation for the indicated
times (0, 1, 3, or 5 days), propidium iodide (30 mmol/l) and
digitonin (600 mmol/l) were added to each well to label cell
nuclei. Cell proliferation was evaluated by measuring the
fluorescence intensity of propidium iodide, as previously
described30 using an infinite F200 (Tecan, Ma¨nnedorf,
Switzerland).
Colony Formation Assays
Anchorage-independent growth was assessed by colony for-
mation in soft agar as previously described.31 Single-cancer
cells (1 104 cells) were diluted in DMEM with 10% FBS and
0.35% Bacto-Agar (Difco, Detroit, MI, USA), and seeded in
six-well plates on top of a 0.7% agar bottom layer without
cells. Cells were incubated for 14 days, and growth medium
(DMEM with 10% FBS) was replaced biweekly. Colonies
were stained with crystal violet (0.005%) for 20min and
counted under a light microscope.
Matrigel Invasion and Migration Assays
Cancer cell migration and invasiveness were assessed by de-
termining the number of cells invading 8-mm pore Transwell
chambers (BD Biosciences). Transwell inserts were coated
with Matrigel (20 mg/well; BD Biosciences, Bedford, MA,
USA) for invasion assays, and without coating for migration
assays. For indirect co-culture experiments, PDAC cell lines
(4 104 cells) were resuspended in 250 ml of DMEM con-
taining 1% FBS, and seeded in the upper chamber, which
was then placed in a 24-well culture dish containing PSCs
(4 104 cells) resuspended in 750 ml of the same medium.
For monoculture experiments using AGR2 knockdown cells,
cancer cells (4 104 cells) were resuspended in 250 ml of
DMEM containing 10% FBS and seeded in the upper chamber,
which was placed in a 24-well culture dish containing 750 ml
of the same medium. Invasion and migrations assays were
performed using Aspc-1 and Hs766T cells for 36 and 24 h,
respectively. Invading or migrating cancer cells were fixed to
the lower surface of the transwell membrane with 70%
ethanol, stained with hematoxylin–eosin and counted in five
random fields at  100 magnification, using an All-in-one
Type Fluorescence Microscope (BZ-9000; Keyence) and BZ-II
image analysis software (Keyence). Results are expressed as
the mean number of cancer cells translocating to the lower
surface.
Indirect Co-Culture of Cancer Cells with PSCs
Indirect co-culture experiments were performed as previously
described.27 Pancreatic cancer cells (1 105 cells) were seeded
in six-well plates (BD Biosciences) in 2ml DMEM supple-
mented with 10% FBS. Human primary-cultured PSCs
(3 105 cells) were seeded into 3-mm pore Transwell
chambers in 1ml DMEM with 10% FBS. The following
day, Transwell chambers seeded with PSCs were placed into
six-well plates containing pancreatic cancer cells, and
incubated up to 48 h in DMEM with 1% FBS.
Treatment with Recombinant Proteins
To identify the factors involved in AGR2 downregulation,
we cultured cancer cells in the presence of recombinant
human TGF-b1, EGF, and FGF-2, which have previously
been shown to induce EMT.24–26 Cancer cells were seeded
in 90-mm dishes (1 105 cells/dish) and incubated for
48 h in DMEM supplemented with 1% FBS with or without
various growth factors (0.5, 1, 2, and 5 ng/ml recom-
binant human TGF-b1 (R&D Systems, Oxon, UK), 1, 10,
and 100 ng/ml recombinant human FGF-2 (Sigma, Basel,
Switzerland), and 1, 10, 20, and 100 ng/ml recombinant
human EGF (Sigma).
Enzyme-Linked Immunosorbent Assay (ELISA) for TGF-
b1 Levels
Secreted TGF-b1 levels were assayed in cell culture super-
natants using the Quantikine human TGF-b1 kit (R&D
Systems). Aspc-1 cells (1 105 cells) were plated in six-well
plates and co-cultured with or without primary-cultured
PSCs (3 105 cells) for 24 h in serum-free DMEM. Super-
natants were then collected and analyzed in accordance with
the manufacturer’s instructions. Cancer cells were co-cul-
tured with PSCs as described above. Each sample was assayed
in triplicate and quantification was obtained using a plate
reader at 450 nm (corrected by subtracting absorbance at
540 nm).
Inhibition of TGF-b Signaling Using Neutralizing
Antibody
For inhibition of TGF-b signaling, PDAC cells were co-cultured
with PSCs as described above, and treated with recombinant
human TGF-b sRII/Fc (rhTbsR-II) (100 ng/ml, 341-BR, R&D
Systems),32 TGF-b neutralizing antibody (10mg/ml, MAB1835,
R&D Systems) or mouse control IgG1 (10 mg/ml, MAB002,
AGR2 downregulation and EMT in PDAC
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R&D Systems) for 48 h in DMEM supplemented with 1%
FBS.
Statistical Analysis
The correlation between two variables was analyzed using
the w2-test or the Fisher exact test, where appropriate.
For survival analysis, disease-free survival was adopted
as primary end points. The survival correlation was
presented using Kaplan–Meier analysis, and the curves
were compared using the log-rank test. Linear regression
analysis was used to examine the association between
mRNA levels of AGR2 and E-cadherin in PDAC cell lines.
For in vitro experiments, continuous variables were expressed
as the mean±s.d. Each experiment was performed in
biological triplicate. Comparison between two groups
was analyzed using the Student’s t-test. Statistical significance
was defined as Po0.05. All statistical analyses were
performed using JMP 9.01 software (SAS Institute, Cary,
NC, USA).
RESULTS
AGR2 Expression in PDAC and Pre-Cancerous Lesions
IHC analyses revealed AGR2 staining in the cytoplasm of
neoplastic cells. All PDAC precursors were positive for AGR2
expression, even in PanIN1A (100%, 10/10) and IPMN with
low-grade dysplasia (100%, 20/20), which represent the most
benign types of PDAC precursor lesions. AGR2 expression
was retained in PanIN2 (100% 5/5) and IPMN with inter-
mediate-grade dysplasia (100%, 19/19). In contrast, AGR2
immunoreactivity was not detected in normal pancreatic
duct specimens of chronic pancreatitis patients (Figure 1).
Clinicopathological findings and IHC characteristics for
AGR2 are summarized in Table 1. Of the 195 PDAC patients,
AGR2 expression was decreased in 54 patients (27.7%).
Decreased AGR2 expression was associated with high histo-
logical grade (G3 (poorly differentiated); refer to structure,
growth pattern of the cancer cells, and nuclear atypia)
(Po0.0001) and high Union for International Cancer
Control stage (4stage II) (P¼ 0.0061).
Reduced Expression of AGR2 Correlates with Markers of
EMT in PDAC
We observed decreased expression of AGR2 in areas of high
histological grade and decreased cell adhesiveness in the
tissue of PDAC patient (Figures 2a–h). Therefore, we
hypothesized that EMT may be associated with AGR2
downregulation. To assess this hypothesis, we investigated the
expression of EMT markers (E-cadherin and vimentin) in
serial sections of PDACs by IHC staining. In Table 1, mem-
branous E-cadherin expression was reduced (o50%) in 68
patients (34.9%) and cytoplasmic vimentin expression was
observed in 36 patients (18.5%), and AGR2 downregulation
Figure 1 Immunohistochemical analysis of anterior gradient 2 (AGR2) in chronic pancreatitis and pre-cancerous lesions. AGR2 expression was not
detected in non-neoplastic ducts of chronic pancreatitis patients (a). AGR2 upregulation was observed in benign PDAC precursor lesions including
PanIN1A (b) and IPMN with low-grade dysplasia (e), and expression was retained in more severe precursor lesions (c, d and f). PanIN, pancreatic
intraepithelial neoplasia; IPMN-L, intraductal papillary mucinous neoplasm with low-grade dysplasia; IPMN-I, intraductal papillary mucinous neoplasm
with intermediate-grade dysplasia; (original magnification: (a)  100, (b)  200, (c)  200, (d)  40, (e)  100, (f)  100).
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was associated with reduced membranous E-cadherin
expression (Po0.0001) and cytoplasmic vimentin expression
(Po0.0001). Areas of reduced AGR2 expression were con-
sistent with those exhibiting induction of EMT (decreased
membranous expression of E-cadherin and positive cyto-
plasmic vimentin expression) (Figures 2c, d, g, h, k, l, o
and p). These data demonstrate that AGR2 downregulation is
correlated with induction of EMT, probing a deeper analysis
of the interaction between these two parameters.
Reduced Expression of AGR2 Correlates with Poor
Prognosis in PDAC Patients
We next examined the relationship between AGR2 expression
and survival of PDAC patients. Univariate analysis revealed
that decreased AGR2 expression was a statistically significant
indicator of adverse prognosis for disease-free survival
(Figure 3a). Conversely, multivariate analysis revealed that
AGR2 downregulation was not an independent predictor of
shorter overall survival (Supplementary Table 2). To examine
the impact of AGR2 and E-cadherin status on disease-free
survival, we determined the disease-free survival rate with
combined AGR2 and E-cadherin status (Figures 3b–d). Low
AGR2 expression was correlated with poor disease-free sur-
vival. Further evaluation on the basis of E-cadherin expres-
sion revealed that lower AGR2 expression correlated with
a lower survival rate in both high- and low-E-cadherin
expression cohorts, although this difference was not statisti-
cally significant (Figures 3c and d). These data suggest that
AGR2 downregulation could contribute to poor prognosis,
but is partially affected by decreased membranous E-cadherin
expression.
AGR2 Expression in Pancreatic Cancer Cell Lines
Analysis of AGR2 expression in a panel of nine pancreatic
cancer cell lines by qRT-PCR revealed significant variation
in expression levels. Epithelial-type cancer cell line (high
E-cadherin, low vimentin; HS766T, H48N, and BxPC-3)
exhibiting cellular adhesiveness retained AGR2 expression,
whereas spindle-shaped mesenchymal-type cancer cell line
(low E-cadherin, high vimentin; MiaPaCa2, SUIT-2, and
HPC-3) expressed relatively low levels of AGR2 (Figure 4a).
Linear regression analysis revealed a strong positive correla-
tion between AGR2 and E-cadherin expression at the mRNA
level (Figure 4b; R2¼ 0.7262, P¼ 0.0035). Taken together,
these results strengthen the hypothesis that AGR2 down-
regulation is correlated with EMT induction.
AGR2 Knockdown Using siRNA
To analyze the function of AGR2 in vitro, we performed
targeted knockdown of AGR2 in PDAC cells using anti-AGR2
siRNA. Efficient knockdown of AGR2 transcript (470%
until 120 h post transfection) was confirmed by qRT-PCR
(Figures 5a and g), and reduced AGR2 protein levels were
confirmed by western blot 72 h post transfection (Figure 5b).
Targeted inhibition of AGR2 in both Aspc-1 and Hs766T cells
led to a significant decrease in anchorage-dependent cell
proliferation (Figure 5c), colony formation (Figure 5d), cell
migration (Figure 5e), and cell invasiveness (Figure 5f)
compared with cells transfected with non-coding negative-
control RNA (Po0.05), except for the colony formation
assay in Hs766T (P¼ 0.0686). AGR2 knockdown did not
alter the expression of epithelial or mesenchymal markers
(E-cadherin and vimentin, respectively), or transcription
factors involved in EMT induction (Snail-1, Snail-2, and
ZEB-1) in PDAC cells (Figure 5g), implying that AGR2 does
Table 1 Clinicopathological characteristics of PDAC patients
(n¼ 195) (*Po0.01)
AGR2 expression Total
Variable High (n¼ 141) Low (n¼ 54) (n¼ 195) P-value
Age (in years) 66.5 (36–86) 63.7 (36–80)
Male/female 84/57 37/17 121 0.2494
Location
Head/body and tail 96/43 33/21 129/63 0.3885
E-cadherin
High expression 114 13 127 o0.0001*
Low expression 27 41 68
Vimentin
Positive 14 22 36 o0.0001*
Negative 127 32 159
Histological grade o0.0001*
G1 (well) 42 2
G2 (moderately) 60 9
G3 (poorly) 27 38
Local invasion 118/139 (84.9%) 49/53 (92.3%) 0.164
Vessel invasion 111/141 (78.7%) 46/53 (86.8%) 0.2024
Lymph node
metastasis
95/141 (67.4%) 43/54 (79.6%) 0.0923
UICC T category
1/2 14 5 19 0.8878
3/4 127 49 176
UICC stage
Stage I/II 137 47 184 0.0061*
Stage III/IV 4 7 11
Abbreviations: AGR2, anterior gradient 2; PDAC, pancreatic ductal adeno-
carcinoma; UICC, Union for International Cancer Control.
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not directly regulate EMT induction in PDAC cells. These
results are consistent with previous reports, but not our IHC
data. It was suggested that correlation with adverse prognosis
and EMT induction in low-AGR2-expressing PDAC patients
by our IHC analysis was not due to loss of AGR2 function
itself. On the basis of these observations, we hypothesize that
other molecules involved in PDAC progression function as
upstream negative regulators of AGR2.
AGR2 Expression Decreased in PDAC Cell Lines
Co-Cultured with PSCs
Among the mechanisms promoting cancer progression,
cancer-stromal interactions have a crucial role in cancer
cells invading the tumor microenvironment, but not in
intraepithelial lesions. To investigate the relationship between
AGR2 downregulation, tumor microenvironment and EMT
induction, we performed co-culture experiments, in which
PDAC cells were indirectly co-cultured with human primary-
cultured PSCs. Co-culture of PDAC cells with primary PSCs
induced EMT, as evidenced by a decrease in E-cadherin and
increase in vimentin, Snail-1, Snail-2, and ZEB-1 mRNA
levels, compared with cancer cell monocultures (Figures 6b
and c), and E-cadherin and vimentin expression was slightly
altered in protein levels. AGR2 expression was decreased in
co-cultured PDAC cells at the mRNA and protein levels
(Figures 6a and d). The results of these indirect co-culture
experiments suggest that soluble factors secreted from PSCs
contribute to AGR2 downregulation in cancer cells.
Figure 2 Histological analyses of human PDAC specimens. Representative images of hematoxylin and eosin (H&E) staining (a–d) and
immunohistochemical staining for anterior gradient 2 (AGR2) (e–h), E-cadherin (i–l), and vimentin (m–p). Each column of figures represent serial
sections of one PDAC patient (a, e, i and m: well differentiated; b, f, j and n: moderately differentiated; c, g, k and o: poorly differentiated; d, h, l and
p: admixed components of well- (arrowhead) and poorly (asterisk) differentiated adenocarcinoma. Low-histological-cellular-grade (well or moderately
differentiated) PDAC retained AGR2 and membranous E-cadherin expression, whereas vimentin expression was absent. Cytoplasmic AGR2 expression
and membranous E-cadherin expression were decreased in parallel with cancer de-differentiation, and positive cytoplasmic vimentin expression was
observed in high-histological-cellular-grade (poorly differentiated) PDAC. E-cadherin expression is seen at the membrane and in the cytoplasm of the
well-differentiated carcinoma, but is decreased in the membrane of the poorly differentiated carcinoma (l; insets). Original magnification: H&E staining
 100, IHC  200.
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AGR2 Downregulation Mediated by TGF-b Signaling
Secreted by PSCs
TGF-b has previously been described as an inducer of EMT33
and a negative regulator of AGR234 in PDAC. We next
examined total levels of secreted TGF-b in co-culture
supernatants of Aspc-1 and PSCs by ELISA. Whereas low
levels of TGF-b were secreted into the medium of Aspc-1
monocultures, the concentration of TGF-b in co-culture
supernatants was 2.5–4.5-fold higher (E1 ng/ml, Figure 6e).
AGR2 expression was decreased following treatment of Panc-
1, Aspc-1, and Capan-2 cells with human recombinant
TGF-b1. High levels of EGF also inhibited AGR2 expression
in Aspc-1 and Capan-2 cells, but not in Panc-1 cells, whereas
treatment with FGF-2 did not alter AGR2 expression
in PDAC cells (Figure 6f). In addition, the level of phos-
phorylated ERK1/2 was elevated in cancer cells co-cultured
with PSCs compared with monocultures. Phosphorylated
Smad2/3 was observed in Panc-1 and Capan-2 cells, but not
in Aspc-1 cells (Figure 6d). AGR2 downregulation was
associated with phosphorylation of ERK1/2 in Panc-1,
Aspc-1, and Capan-2 cells. To confirm whether AGR2
expression is reduced by the function of TGF-b1 in PDAC
cells, we performed co-culture experiments inhibiting
TGF-b signaling using a TGF-b1 neutralizing antibody and
recombinant human TGF-b receptor type II Fc Chimera.
AGR2 mRNA expression was restored in PDAC cells co-
cultured with PSCs following inhibition of TGF-b signaling
(Figure 6g). These results indicate that TGF-b secreted from
PSCs may partially contribute to downregulation of AGR2.
DISCUSSION
In this study, we demonstrated that AGR2 downregulation
occurred in high histological grade PDAC in association with
EMT induction, and correlated with poor outcome in PDAC
patients. We also demonstrated that AGR2 expression was
downregulated in PDAC cells following co-culture with PSCs,
consistent with EMT induction, and TGF-b1 secreted from
PSCs partially contribute to its AGR2 downregulation.
Our IHC analyses revealed that AGR2 expression was
upregulated during neoplastic initiation and subsequently
downregulated during cancer progression, cancer cell
de-differentiation, and EMT induction. This suggests that
AGR2 may contribute to early neoplastic initiation by
increasing proliferation and migration rather than progres-
sion and metastasis, and that downregulation of AGR2
occurs in advanced- and high-grade PDAC. IHC analyses of
EMT markers in these specimens also demonstrated that
AGR2 downregulation was correlated with EMT induction in
Figure 3 Kaplan–Meier survival curves demonstrating disease-free survival in PDAC patients according to anterior gradient 2 (AGR2) and E-cadherin
expression. Low AGR2 expression was associated with poor prognosis in disease-free survival (a; log-rank test; Po0.0001). Disease-free survival rate
with combined AGR2 and E-cadherin status (b). In both high- and low-E-cadherin expression cohorts, low AGR2 expression was associated with a lower
survival rate (c and d).
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PDAC patients. In this study, AGR2 downregulation occurred
in only 28% of PDAC patients. It should be noted that AGR2
expression can also be upregulated in PDAC, as other pub-
lications have suggested.14,16
Previous reports have documented conflicting results re-
garding the prognostic value of AGR2 expression. In prostate
cancer tissue, AGR2 downregulation correlated with
increased Gleason grade, a histological grading system of
prostate cancer, and increased cancer recurrence in Gleason
grades 4 or 5.35 A more recent report demonstrated that high
AGR2 expression and low CD10 expression were favorable
prognostic markers in prostate cancer.36 In contrast, another
reported that increased AGR2 expression was correlated with
poorer outcome in prostate cancer.13 Similar controversy
regarding the prognostic value of AGR2 expression has been
observed in breast cancer; with AGR2 upregulation asso-
ciated with favorable prognosis in one study,37 and with poor
prognosis in another independent analysis.11
Previous studies of PDAC did not identify a correlation
between AGR2 expression and prognosis.15 Our univariate
analysis revealed that AGR2 downregulation correlated with
poor prognosis in PDAC patients. In contrast, multivariate
analysis revealed that AGR2 expression was not a poor
prognostic marker, whereas downregulation of E-cadherin
had significant prognostic value (Supplementary Table 2).
Furthermore, division of patients into two groups based on
E-cadherin expression reveals that low-AGR2 expression
tends to be an indicator of shorter survival, although this
difference was not statistically significant (Figures 3c and d).
It can be said that AGR2 has a strong correlation with
E-cadherin and makes it as a strong confounding factor.
Indeed, exclusion of E-cadherin expression from the multi-
variate analysis revealed that AGR2 downregulation was an
independent prognostic marker (data not shown), suggesting
the strong correlation between AGR2 downregulation and
decreased membranous E-cadherin expression. In the view of
a prognostic marker, as AGR2 is secreted into the pancreatic
fluid, unlike E-cadherin or vimentin,38 it may represent a
useful and convenient pre-operative prognostic marker. To
the best of our knowledge, our study is the first report
demonstrating the prognostic significance of decreased AGR2
expression in PDAC patients.
Whereas AGR2 has been previously described as an on-
coprotein capable of promoting cancer cell proliferation,
invasiveness, and migration in various PDAC cell lines,14 our
IHC study revealed that AGR2 was downregulated during
PDAC progression and this was associated with poor pro-
gnosis. Consistent with our IHC results in PDAC, recent
reports reveal that AGR2 immunoreactivity is frequently lost
in colorectal carcinoma, and may represent a novel pro-
gnostic indicator for overall patient survival.39
Discrepancy between pro-oncogenic function of AGR2 as
previously reported and the prognostic significance of AGR2
downregulation may have several explanations. First, the
biological outcome of altered AGR2 expression may depend
on the origin of tumor development. For example, caveolin-
1, an essential constituent protein of specialized membrane
invaginations referred to as caveolae, was upregulated in
prostate cancer tissue,40 but downregulated in colon cancer
tissue.41 Targeted knockdown of AGR2 in PDAC cells using
siRNA revealed that AGR2 silencing suppressed the prolife-
ration, invasiveness, and migration of Aspc-1 and Hs766T
cells, as previously reported in other PDAC cell lines (BxPC-3,
SU8686, CFPAC-1, and MPanc-96),14 but did not alter EMT
markers. These data suggest that AGR2 promotes cancer
Figure 4 Quantitative reverse transcription-PCR for anterior gradient 2
(AGR2) expression in pancreatic cancer cell lines. AGR2 expression differed
in the various pancreatic cancer cell lines. High AGR2-expressing cell lines
exhibited overexpression of vimentin and reduced E-cadherin expression.
Epithelial-type cancer cells (HS766T, H48N, and BxPC-3), retained cellular
adhesiveness and AGR2 expression, whereas mesenchymal-type cancer
cell lines (MiaPaCa2, SUIT-2, and HPC-3) exhibiting spindle-shaped
morphology expressed low levels of AGR2. AGR2 and E-cadherin
expression was very low and vimentin expression was quite high in the
primary-cultured pancreatic stellate cells (PSCs) (a). Linear regression
analysis demonstrated a strong positive correlation between AGR2 and
E-cadherin messenger RNA (mRNA) levels (b: R2¼ 0.7262, P¼ 0.0035).
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Figure 5 Targeted inhibition of anterior gradient 2 (AGR2) using small-interfering RNA (siRNA). AGR2 silencing was confirmed following transfection of
Aspc-1 and Hs766T cells with AGR2-specific siRNA by quantitative reverse transcription (qRT)-PCR (a) 48, 72, and 120 h, and immunoblot analysis 72 h
post transfection, respectively (b). E-cadherin and vimentin expression levels were not altered by AGR2 knockdown as assessed by immunoblot analysis
(b). AGR2 knockdown significantly reduced cell proliferation (c), colony formation (d), cell migration (e), and cell invasiveness (f) in Aspc-1 and Hs766T
cells (Po0.01), except for the colony formation assay in Hs766T cells (P¼ 0.0686). AGR2 knockdown did not alter messenger RNA (mRNA) levels of
epithelial–mesenchymal transition markers, E-cadherin, vimentin, Snail-1, Snail-2, and ZEB-1 (g). Data represent the mean values of triplicate
experiments (*Po0.01, versus control). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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Figure 6 Indirect co-culture experiment of pancreatic ductal adenocarcinoma (PDAC) cells with pancreatic stellate cell (PSCs) and treatment with
recombinant growth factors. Anterior gradient 2 (AGR2) expression was decreased in PDAC cells co-cultured with PSCs using an indirect co-culture
system (a) in accordance with epithelial–mesenchymal transition induction (E-cadherin downregulation (b) and overexpression of vimentin, Snail-1,
Snail-2 and ZEB-1 (c)) by quantitative reverse transcription-PCR (*Po0.01, versus monocultures). Decreased expression of AGR2 was observed in co-
cultured cancer cells compared with monocultures. Decreased AGR2 expression was also associated with increased levels of phosphorylated Smad2/3
and ERK1/2, with the exception of phosphorylated Smad2/3 in Aspc-1 (d). E-cadherin and vimentin expression were also slightly altered at the protein
level (d). Enzyme-linked immunosorbent assays revealed that total, secreted transforming growth factor beta-1 (TGF-b1) levels were higher in co-culture
supernatants than that of monocultures (e: *Po0.001, versus the medium of Aspc-1 monocultures). Treatment with recombinant proteins showed that
reduced expression of AGR2 was observed by TGF-b1 in all PDAC cells examined and by high-dose epidermal growth factor (EGF) in Aspc-1 and
Capan-2 cells (f). AGR2 expression was decreased by TGF-b1 or co-cultured with PSCs, and restored by inhibition of TGF-b signaling (g). Data represent
the mean values of triplicate experiments (*Po0.01, versus control). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; FGF-2, fibroblast growth
factor 2; mRNA, messenger RNA.
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progression, but does not induce EMT or mesenchymal–
epithelial transition in PDAC patients. Second, the effect of
AGR2 expression may also be dependent on tumor stage.
IHC analyses revealed that AGR2 was expressed in precursor
PDAC lesions, and its expression was higher than in PDAC. It
was proposed that the pro-oncogenic function of AGR2 may
be active during early tumor development and promote
neoplastic initiation, with TGF-b secreted from PSCs in the
cancer stroma functioning as an upstream negative regulator
of AGR2 at the late stage of cancer progression. Thus, it was
suggested that the oncogenic function of AGR2 exerted little
influence on prognosis in PDAC patients. Third, AGR2
downregulation in PDAC was caused by morphological and
phenotypic alterations during pancreatic cancer progression.
We demonstrated that AGR2 expression was decreased in
parallel with EMT induction, characterized by decreased
membranous E-cadherin expression and increased cyto-
plasmic vimentin expression in IHC analyses. On the basis of
these observations, we hypothesized that AGR2 downregula-
tion may be mediated by upstream regulators that function as
EMT inducers.
PSCs are one of the most important cell populations in the
pancreatic cancer stroma. PSCs are also observed surround-
ing PanIN lesions; however, it has been reported that the
cellular density of PSCs is lower than that of PDAC, and that
the phenotypic characteristics of PSCs surrounding PanINs
may be different from that in PDAC.42 As cancer cells invade
the stroma, destructing the basement membrane, they interact
with stromal cells including PSCs. This interaction promotes
tumor formation and metastasis induced by secreted soluble
factors from stromal cells, including various growth factors
and cytokines. Whereas AGR2 itself promotes cancer initia-
tion in PDAC development, it was suggested that other pro-
oncogenic factors secreted from cancer microenvironments
also contribute to cancer cell invasiveness. AGR2 expression
was consequently reduced following induction of EMT
(alteration to mesenchymal morphology) and the acquisi-
tion of a highly aggressive phenotype by these secreted
factors. To identify such soluble factors associated with AGR2
downregulation in PDAC cells, we cultured PDAC cells with
culture medium containing various recombinant growth
factors known as EMT-inducible factors and secreted from
Figure 6 Continued.
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PSCs, suggesting that AGR2 downregulation may occur in
advanced PDAC cells by this factor secreted from PSCs in
cancer stroma.
A recent study demonstrated that AGR2 expression is
suppressed in Panc-1 cells with wild-type Smad4 by a cano-
nical TGF-b/Smad signaling pathway;34 however, our study
revealed that TGF-b treatment reduced AGR2 expression in
not only Capan-2 and Panc-1, but also Aspc-1 cells harboring
Smad4 mutation.43 The concentration of TGF-b in cell
supernatants co-cultured with PSCs, as assessed by ELISA,
was E1000 pg/ml. Importantly, this level was sufficient to
mediate AGR2 downregulation. TGF-b also stimulates
phosphorylation of ERK1/2 through a Smad-independent
pathway.44 Co-culture experiments demonstrated that
phosphorylation of ERK1/2 occurred in parallel with AGR2
downregulation. This suggests that TGF-b signaling was
activated in the PDAC co-culture setting regardless of DPC4
mutation, and TGF-b-mediated downregulation of AGR2
also occurs via a Smad-independent pathway, although the
exact mechanism(s) underlying the downregulation of AGR2
by TGF-b signaling remains unclear. These results are
schematically summarized in Figure 7.
Collectively, although the complete mechanisms of AGR2
downregulation accompanying EMT induction remain un-
clear, we demonstrated that AGR2 is downregulated in PDAC
compared with pre-malignant lesions, and AGR2 expression
may be a favorable prognostic marker. Targeted silencing of
AGR2 using siRNA revealed that AGR2 promotes cancer cell
proliferation, migration, and invasion, confirming previous
reports that AGR2 itself functions as an oncoprotein.
Reduced AGR2 expression was detected in PDAC cell lines
co-cultured with primary-cultured PSC, in parallel with EMT
induction. These results suggest that reduced AGR2 expres-
sion does not cause EMT, but is the result of aggressive
phenotype in advanced PDAC.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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